Adverse events in patients with LDL-C <0.65 mmol/L (<25 mg/dL) or <0.39 mmol/L (<15 mg/dL) during alirocumab treatment for up to 104 weeks: data from 14 randomized trials
University of Iowa, Iowa (United States of America)
12
presentations
0
follower
19
more
presentations
in this session
Nurse-led telephone-based follow-up of secondary prevention after acute myocardial infarction: one-year results from the randomized controlled NAILED-ACS trial.
Inhibition of acetylcholinesterase by bromide pyridostigmine prevents ventricular dysfunction, autonomic and reduce inflammatory profile in rats treated previously to myocardial infarction